| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms |
|
Medicine details |
|
| Medicine name | momelotinib (Omjjara®) |
| Formulation | tablet |
| Reference number | 2467 |
| Indication | Treatment of adults with disease-related splenomegaly or symptoms with myelofibrosis |
| Company | GSK |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/03/2023 |
| NICE guidance | TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms |